Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/24/18 (What's New)

Summary

  • ALLY-3: daclatasvir plus sofosbuvir for 12 weeks was associated with high SVR rates among treatment-naive and treatment-experienced noncirrhotic patients with genotype 3 HCV infection in the phase III open-label ALLY-3 trial[Nelson 2015]
    • SVR rates considerably lower (63%) among patients with cirrhosis, regardless of treatment experience
  • ALLY-3+: 90% SVR12 rate with daclatasvir plus sofosbuvir and ribavirin for 12 or 16 weeks in patients with genotype 3 HCV infection and advanced fibrosis or compensated cirrhosis[Leroy 2016]

    Action required